Antibodies market forecast to hit $666.72B by 2030

The Business Research Company says the global antibodies market will grow from $381.67 billion in 2026 to $666.72 billion by 2030, driven by biologic therapies, immunology research and rising autoimmune disease cases. North America led the market in 2025, while Asia-Pacific is projected to grow fastest through 2030.

Why it matters: - The antibodies market is expanding fast because antibody-based drugs are becoming more central to cancer care, autoimmune disease treatment and other precision therapies. - A larger market also signals more demand for biologics manufacturing capacity, research spending and biosimilar development. - Rising autoimmune disease prevalence is increasing the number of patients who may need antibody treatments.

What happened: - The Business Research Company published its Antibodies Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report values the market at $381.67 billion in 2026, up from $331.01 billion in 2025. - The report projects the market will reach $666.72 billion by 2030. - The company projects a 15.3% CAGR for 2026 and a 15.0% CAGR through 2030. - The report includes a free sample at Download a free sample of the antibodies market report. - The full report is available at View the full antibodies market report.

The details: - Growth through 2026 is tied to breakthroughs in immunology research, higher investment in biologic drug development, wider oncology use, more autoimmune disorders and better antibody manufacturing technologies. - Forecast growth through 2030 is linked to precision immunotherapy adoption, biosimilar antibody pipelines, personalized medicine and more global biologics production capacity. - Key market trends include monoclonal antibody development, antibody-drug conjugates, targeted immune treatments, use in chronic disease management and scalable biomanufacturing. - Antibodies are proteins produced by the immune system that bind to antigens on bacteria, viruses and other foreign substances. - That binding can neutralize pathogens directly or mark them for removal by other immune cells. - Antibodies are a core part of the adaptive immune response and are tailored to specific antigens. - Autoimmune diseases such as rheumatoid arthritis, lupus and multiple sclerosis are helping drive demand for antibody therapies. - In May 2024, the Multiple Sclerosis International Federation reported that the global population living with multiple sclerosis rose from 2.8 million in 2020 to 2.9 million in 2023. - North America held the largest share of the market in 2025, supported by advanced healthcare infrastructure, strong research capabilities and high biologics adoption. - Asia-Pacific is expected to be the fastest-growing region during the forecast period because of higher healthcare spending, rising awareness of antibody therapies, growing biologics manufacturing and a larger patient base. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Between the lines: - The forecast suggests antibodies are moving deeper into mainstream treatment strategies, especially where targeted therapies can replace broader approaches. - North America’s lead reflects mature infrastructure and research strength, while Asia-Pacific’s growth points to where new manufacturing and demand may accelerate next. - The report’s emphasis on biosimilars and scalable production signals a market that is shifting from pure innovation toward broader commercialization.

What's next: - The market outlook now depends on how quickly precision immunotherapies, biosimilars and manufacturing capacity expand. - The company is inviting industry outreach through its expert contacts and email channel. - The Business Research Company is promoting its report through LinkedIn and other social channels.